HIV-1 (IIIB Strain) Purified Virus-细胞株/菌种-试剂-生物在线
HIV-1 (IIIB Strain) Purified Virus

HIV-1 (IIIB Strain) Purified Virus

商家询价

产品名称: HIV-1 (IIIB Strain) Purified Virus

英文名称: HIV-1 (IIIB Strain) Purified Virus

产品编号: HIV-1 (IIIB Strain) Purified Virus

产品价格: 0

产品产地: 美国

品牌商标:

更新时间: 2023-09-19T20:51:30

使用范围: null

麦亘生物
  • 联系人 :
  • 地址 : 东莞市松山湖留创园15栋306室
  • 邮编 : 523808
  • 所在区域 : 广东
  • 电话 : 189****2687
  • 传真 : 0769-22890556
  • 邮箱 : tao.maigen@live.cn

 


东莞市麦亘生物科技有限公司

联系电话:0769-22890558 
Description(名称) HIV-1 (IIIB Strain) Purified Virus
Catalog #(货号) 10-118-000
 Size(规格) 1.0 mg
 Price(价格)   请联系:0769-2289-0558, 0769-22890598, QQ:2533190771

                                               Biohazard Category A

 

 
All customers ordering biohazardous products must have an Acceptance of Responsibility form on record with ABI.Click here to download.

 

 

Description(产品描述)

 

Human Immunodeficiency Virus type 1 (IIIB strain) propagated in H9 cells and purified from culture supernatant and cells showing cytopathic effect.

For research use only. Not for use in diagnostic procedures.

Purified Infectious Viruses offered by ABI are a valuable asset for the research community. We have experience with many virus families, including: Orthomyxoviridae, Paramyxoviridae, Retroviridae, Poxviridae, Herpesviridae, Picornaviridae, Adenoviridae, Togaviridae, and others. ABI also offers custom start-to-finish virus propagation, purification and characterization services.

 

Details(注意事项):

Shipping and Storage: This product is shipped frozen on dry ice. Store at -70°C upon receipt. Avoid multiple freeze-thaw cycles as product degradation may result.

Recommendations: Upon thawing, centrifuge the vial for a few seconds to remove residual droplets from the lid.

Safe Handling Recommendation: This preparation of HIV is a BIOHAZARDOUS material containing ACTIVE VIRUSand should be handled in accordance with biosafety guidelines defined in the BMBL, NIH-CDC HHS Publication No. 93-8395.

 

Applications for use(适用范围):

  • In vitro Infectivity Assay
  • Antiviral Studies
  • Animal Experimentation
  • Nucleic Acid Extraction
  • Spiking Studies
  • ELISpot Assay
  • Virus Neutralization Assay
  • Virus Ultrastructural Studies

 

Quality control testing includes(质量控制检测包括):

  • Sterility
  • TCID50
  • p24
  • Protein Concentration
  • Virus Particle Count

 

Certificate of Analysis(分析报告):

 

Reference Articles(已发表参考文献):

 

Reuter MA, Pecora ND, Harding CV, Canaday DH, McDonald D. “Mycobacterium tuberculosis Promotes HIV trans-Infection and Suppresses Major Histocompatibility Complex Class II Antigen Processing by Dendritic Cells.” Journal of Virology. 2010;84(17):8549-8560.

Thakkar N, Pirrone V, Passic S, et al. “Specific Interactions between the Viral Coreceptor CXCR4 and the Biguanide-Based Compound NB325 Mediate Inhibition of Human Immunodeficiency Virus Type 1 Infection.” Antimicrobial Agents and Chemotherapy. 2009;53(2):631-638.

Gulzar N, Balasubramanian S, Harris G, Sanchez-Dardon J, Copeland KFT. “Infection of CD8+CD45RO+ Memory T-Cells by HIV-1 and Their Proliferative Response.” The Open AIDS Journal. 2008;2. Abstract

Cihlar T, Ray AS, Boojamra CG, et al. “Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131.” Antimicrobial Agents and Chemotherapy. 2008;52(2).

Dudani AK, Martyres A, Fliss H. “Rapid Preparation of Preventive and Therapeutic Whole-Killed Retroviral Vaccines Using the Microbicide Taurine Chloramine.” AIDS Research and Human Retroviruses. 2008;24(4):635-642.

Gallina DJ. Compositions and Methods of Treating Retroviral Infections.; 2007.

Zheng NN, McElrath MJ, Sow P-S, et al. “Role of Human Immunodeficiency Virus (HIV)-Specific T-Cell Immunity in Control of Dual HIV-1 and HIV-2 Infection.” Journal of Virology. 2007;81(17):9061-9071.

Neurath RA, Strick N, Li Y-Y. “Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides.” BMC Infectious Diseases. 2006;6(1):150.

Nguyen DG, Wolff KC, Yin H, Caldwell JS, Kuhen KL. ““UnPAKing” Human Immunodeficiency Virus (HIV) Replication: Using Small Interfering RNA Screening To Identify Novel Cofactors and Elucidate the Role of Group I PAKs in HIV Infection.” Journal of Virology. 2006;80(1):130-137.

Vázquez N, Greenwell-Wild T, Marinos NJ, et al. “Human Immunodeficiency Virus Type 1-Induced Macrophage Gene Expression Includes the p21 Gene, a Target for Viral Regulation.” Journal of Virology. 2005;79(7).

Scordi-Bello IA, Mosoian A, He C, et al. “Candidate Sulfonated and Sulfated Topical Microbicides: Comparison of Anti-Human Immunodeficiency Virus Activities and Mechanisms of Action.” Antimicrobial Agents and Chemotherapy. 2005;49(9):3607-3615.

Mulato AS, Ho ES, Cihlar T. “Nonsteroidal Anti-Inflammatory Drugs Efficiently Reduce the Transport and Cytotoxicity of Adefovir Mediated by the Human Renal Organic Anion Transporter 1.” The Journal of Pharmacology and Experimental Therapeutics. 2000;295(1).

Moss RB, Giermakowska W, Wallace MR, Savary J, Jensen F, Carlo DJ. “T-Helper-Cell Proliferative Responses to Whole-Killed Human Immunodeficiency Virus Type 1 (HIV-1) and p24 Antigens of Different Clades in HIV-1-Infected Subjects Vaccinated with HIV-1 Immunogen (Remune).” Clinical and Diagnostic Laboratory Immunology. 2000;7(5).